Key Highlights
- 12.88% is the intraday decline to USD 16.37 for Omeros Corporation (NASDAQ:OMER) per published market data (October 16, 2026 intraday). The gap was -4.52% and the move from the open was -8.59%, on 809,284 shares, 0.9x the average volume.
- USD 28.5 million was Q2 2026 net revenue from YARTEMLEA (narsoplimab), up from USD 9.9 million in Q1, per the release dated August 12, 2026. Gross revenue was USD 32.2 million, and gross-to-net adjustments were 11.5%.
- USD 16.37 compares with USD 8.67, the price after the June 26, 2026 negative CHMP opinion, a gain of 88.8% (own arithmetic on two published quotes). The implied prior close of USD 18.79 was 116.7% above that level.
- USD 132.0 million was cash and short-term investments at June 30, 2026, while the shareholders' deficit was USD 51.3 million, per the August 12, 2026 release. Operating cash flow was positive USD 4.1 million for the quarter.
Price Action and Catalyst Review
No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026, although the table labels the session as News. Published market data show USD 16.37, down 12.88% from an implied prior close of USD 18.79 (own arithmetic). The gap of -4.52% set the open at USD 17.94, and the stock fell a further 8.59% from the open, so the decline built through the session. The move reverses part of a rally that followed the Q2 report, with causation not established by any filing.
Liquidity and Trading Activity
Volume of 809,284 shares at USD 16.37 equals USD 13.25 million of turnover (own arithmetic), or 1.02% of the USD 1.3 billion market capitalisation, which the table rounds. Relative volume of 0.9x implies an average of 899,204 shares (own arithmetic), so the label of unusual volume is not supported. Market capitalisation divided by price gives 79.4 million shares (own arithmetic). The RSI is 36.3. A beta of 2.55 and a 19.12% fall on June 26 per published data show the stock moves sharply on regulatory news.
Convertible Notes, Regulatory Path and Risks
In July 2026 Omeros repurchased USD 30.5 million of 2029 notes for USD 60.2 million, or 197.4% of principal (own arithmetic), leaving USD 40.3 million and cutting conversion shares from 11.4 million to 6.5 million. The implied conversion price is USD 6.20 (own arithmetic), far below the quote, so the notes carry equity-like dilution. The EMA re-examination of narsoplimab in TA-TMA is pending after the negative CHMP opinion, and two YARTEMLEA studies are due to begin enrolling by year-end 2026. Net income of USD 13.2 million included non-cash derivative gains, and adjusted net income was USD 1.8 million.
Where Things Stand
The drop is not explained by any filing reviewed, so it is best read as a reversal of a rally rather than a reaction to news. Omeros Corporation (NASDAQ:OMER) reported USD 28.5 million of Q2 YARTEMLEA net revenue and positive operating cash flow, yet the stock fell 12.88% on 0.9x average volume and trades at 11.4 times annualised Q2 net revenue (own arithmetic). The balance of evidence is commercial progress against a shareholders' deficit, convertible dilution and a pending European decision. The next dated events are the EMA re-examination outcome, which has no confirmed date, and enrolment starts by year-end 2026.






Please wait processing your request...